Fourpath Capital Management’s GSK GSK Stock Holding History

Fourpath Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14,759	Closed	-$724K	–	232
2025 Q4	$724K	Sell	14,759 -4,067	-22%	-$190K	0.1%	119
2025 Q3	$813K	Buy	18,826 +20	+0.1%	+$781	0.12%	114
2025 Q2	$722K	Buy	+18,806	New	+$719K	0.11%	112
2024 Q4	–	Sell	-5,276	Closed	-$216K	–	460
2024 Q3	$216K	Buy	+5,276	New	+$216K	0.04%	213
2022 Q3	–	Sell	-4,082	Closed	-$222K	–	120
2022 Q2	$222K	Sell	4,082 -30	-0.7%	-$1.66K	0.14%	123
2022 Q1	$224K	Hold	4,112	–	–	0.09%	140
2021 Q4	$227K	Buy	+4,112	New	+$214K	0.09%	151

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Fourpath Capital Management's GSK Position: Q1 2026 in Review

Fourpath Capital Management sold out of GSK (GSK) in Q1 2026, closing a stake of 14,759 shares — an estimated $724K sold.

Fourpath Capital Management first reported a position in GSK in Q4 2021 and held it in 7 quarters. The position peaked at $813K in Q3 2025. 1,035 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Fourpath Capital Management reported no remaining GSK position as of Q1 2026 after selling out during the quarter.
Fourpath Capital Management sold 14,759 GSK shares in Q1 2026, an estimated $724K.
Fourpath Capital Management first reported a position in GSK in Q4 2021 and held it in 7 quarters.
Fourpath Capital Management's GSK position peaked at $813K in Q3 2025.
1,035 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Fourpath Capital Management's 13F filing for Q1 2026, filed 1 May 2026.